icon
icon
icon
icon
Upgrade
icon

Novavax (NVAX.US) rises over 12% after selling its Czech factory

AInvestFriday, Dec 6, 2024 10:30 am ET
1min read

Novavax NVAX.US shares climbed on Friday, up more than 12% at the time of writing to $9.355. The news was that Novavax had sold its manufacturing facility in the Czech Republic to Novo Nordisk NVO.US for $200 million. According to a statement released on Wednesday, Novavax will transfer a 150,000 square foot recombinant protein manufacturing facility and associated buildings, existing workforce, and all related and necessary infrastructure to Novo Nordisk. Novavax expects the sale of the facility to reduce its annual operating costs by approximately $8 million, in addition to the $190 million in cash payments in 2024 and an additional $10 million in 2025. Novavax President and CEO John C. Jacobs said, "The decision to sell the Novavax manufacturing plant in the Czech Republic aligns with our previously announced commitment to transform Novavax into a more streamlined and agile organization, focused on our pipeline assets and technology platforms."

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.